Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (11733)	3/24/1999 10:39:00 AM
From: Tony B	Read Replies (1) \| Respond to of 56535

TJ - HAHAHAHAHA! I knew snerd and I were having an affect on you! llater, Tony B

To: Trader J who wrote (11733)	3/24/1999 10:41:00 AM
From: MMK	Respond to of 56535

TJ...LOLOL!!! Boy, aren't you perky this morning! Glad to see you are hangin' in there. Keep it up! LOL...MMK...this could be a looooong day :0

To: Trader J who wrote (11733)	3/24/1999 10:41:00 AM
From: JamesT.	Respond to of 56535

TraderJ...Ha!..Have you and TonyB been hangin out??!! (no pun intended!!) (LOL) JamesT

To: Trader J who wrote (11733)	3/24/1999 11:04:00 AM
From: Mkilloran	Read Replies (1) \| Respond to of 56535

Trader J...VVUS has been able to penetrate 25% of the UK and Sweden ED marketplace going head to head with Viagra. Good marketing by Astra,,soon to be combined Astra/Zeneca will prove out in Europe in the 2nd qtr as Muse is launched for sale across Europe. What they lack is a USA sales force...Look for a sales partner next qtr ...IMO Astra/Zeneca will be the partner after they finish their merger April 6th The R&D pipeline has Alibra their second generation ED male product in Phase III FDA testing, look for final request for FDA approval in the 3rd qtr, the bigger news in the R&D pipeline is a product for female sexual dysfunction that will be a cream that is locally applied to the female. More items in the pipline for ED and non-ED products. The new CFO has expenses under control ...the worm is turning.